Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Author(s):
Poelgeest, M.I.E. van; Welters, M.J.P.; Vermeij, R.; Stynenbosch, L.F.M.; Loof, N.M.; Berends-van der Meer, D.M.A.; Lowik, M.J.G.; Hamming, I.L.E.; Esch, E.M.G. van; Hellebrekers, B.W.J.; Beurden, M. van; Schreuder, H.W.; Kagie, M.J.; Trimbos, J.B.M.Z.; Fathers, L.M.; Daemen, T.; Hollema, H.; Valentijn, A.R.P.M.; Oostendorp, J.; Oude Elberink, H.N.G.; Fleuren, G.J.; Bosse, T.; Kenter, G.G.; Stijnen, T. (0000-0001-9733-969X); Nijman, H.W.; Melief, C.J.M.; Burg, S.H. van der (0000-0002-6556-0354)
Published
2016
Publication type
Article / Letter to editor

Abstract

Conclusions: This new study confirms that clinical efficacy of ISA101 vaccination is related to the strength of vaccine-induced HPV16-specific T-cell immunity and is an effective therapy for HPV16-induced high-grade VIN/VaIN. (C) 2016 AACR.

Date issued
2016-05-15
Language
English
Publisher
AMER ASSOC CANCER RESEARCH
Is part of
Clinical Cancer Research (2016), Vol. 22, no. 10, p. 2342-2350
hdl
1887/99385
doi
10.1158/1078-0432.CCR-15-2594